Therapeutics Development Services

Poly (ADP-ribose) polymerase (PARP) inhibitors have become a transformative treatment for the treatment of diseases, including cancer. At Alfa Cytology, we specialize in the preclinical discovery of PARP inhibitors and facilitate the development of innovative therapies for cancer, metabolic diseases, and cardiovascular diseases.

Introduction to PARP Inhibitor

PARP (poly (ADP-ribose) polymerase) has indeed emerged as an important therapeutic target with diverse applications in a number of disease areas such as cancer, cardiovascular diseases, neurological disorders and metabolic diseases. The key role of PARP and the therapeutic potential of PARP inhibitors in these diseases are described in detail below.

Fig. 1 The key role of PARP. (Curtin N. J., et al. 2022)

Our Services

At Alfa Cytology, we have established a comprehensive suite of services dedicated to the development of PARP peptide inhibitors. Our team of experts leverages their extensive knowledge and state-of-the-art capabilities to guide our clients through every step of the drug discovery process.

Diverse Diseases

Diverse Drug Discovery Strategies

Preclinical Drug Development Services

Our Services Workflow

Alfa Cytology's unwavering commitment to scientific excellence and our deep understanding of PARP biology position us as the preferred partner for the development of PARP inhibitors. Our multidisciplinary team of experts stands ready to collaborate with you, leveraging our proven track record in drug development to accelerate your path to transformative therapies across a wide range of disease indications. Contact us to learn more about how our comprehensive services can support your drug discovery and development initiatives.

For research use only. Not intended for any clinical use.